Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) has been assigned a consensus rating of “Hold” from the eight research firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating on […]
Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its price objective boosted by research analysts at The Goldman Sachs Group from $28.00 to $31.00 in a research report issued on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. The Goldman Sachs Group’s target price would suggest a potential upside of […]